FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions

Key Points:

• The FDA has approved Foundayo™ (orforglipron), Eli Lilly's second obesity medicine, for adults with obesity or overweight with weight-related medical problems, to be used alongside diet and exercise for weight loss and maintenance.
• In the ATTAIN-1 clinical trial, adults on the highest dose of Foundayo lost an average of 27.3 pounds (12.4%) compared to 2.2 pounds (0.9%) with placebo, demonstrating significant efficacy in weight reduction.
• Foundayo is a once-daily oral GLP-1 receptor agonist that can be taken anytime without food or water restrictions, and it will be available via LillyDirect® starting April 6, with pricing as low as $25 per month for commercially insured patients and $149 for self-pay.
• The medication may cause serious side effects including thyroid tumors, pancreatitis, and dehydration, and is not recommended for use with other GLP-1 receptor agonists; patients should be monitored for symptoms such as neck lumps or severe abdominal pain.
• Lilly plans international launches following approvals in over 40 countries and emphasizes accessibility, including a savings card for commercial insurance holders and potential Medicare Part D coverage starting July 2026.